Drug Trial Radar · NCT04660539
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Mar 2, 2021
Primary completion
May 28, 2024
Study completion May 28, 2024
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, single-arm, open-label study will evaluate the long-term safety and efficacy of satralizumab in participants with neuromyelitis optica spectrum disorder (NMOSD) who completed open-label extension (OLE) period of studies BN40898 and BN40900. Participants will receive satralizumab as monotherapy or in combination with one of the following background immunosuppressive treatments: azathioprine (AZA), mycophenolate mofetil (MMF), or oral corticosteroids.
Conditions
- Neuromyelitis Optica Spectrum Disorder
Interventions
satralizumabDrug
Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years
azathioprine (AZA)Drug
Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
mycophenolate mofetil (MMF)Drug
Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day
oral corticosteroidsDrug
Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to 523 weeks
- Number of Participants With Adverse Events of Special Interest (AESIs) and Selected AEsTime frame: Baseline up to 523 weeks
Locations
53 sites in 18 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
University of Miami
Miami, Florida
Columbus Research and Wellness
Columbus, Georgia
University of Chicago
Chicago, Illinois
Consultants in Neurology Ltd
Northbrook, Illinois
OSF Saint Francis Medical Center
Peoria, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Wayne State University; UHC-4H
Detroit, Michigan
The Neurological Institute PA
Charlotte, North Carolina
OhioHealth Research Institute
Columbus, Ohio
Jefferson Hospital For Neuroscience; Jefferson Neurology Associates
Philadelphia, Pennsylvania
University of Texas Southwestern Medical Center
Dallas, Texas
Central Texas Neurology Consultants
Round Rock, Texas
UMHAT 'Dr. Georgi Stranski', EAD
Pleven, Bulgaria
Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv. Naum EAD
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment Aleksandrovska EAD
Sofia, Bulgaria
MS Clinical Trials Group
Vancouver, British Columbia, Canada
Centre hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
Clinical Hospital Centre Osijek
Osijek, Croatia
Ruhr Universitat Bochum
Bochum, Germany
Jahn Ferenc Del-Pesti Korhaz es Rendelointezet
Budapest, Hungary
Azienda Ospedaliera Sant'Andrea
Rome, Lazio, Italy
Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele
Catania, Sicily, Italy
Kyushu University Hospital
Fukuoka, Japan
Tohoku University Hospital
Miyagi, Japan
Niigata University Medical & Dental Hospital
Niigata, Japan
Osaka University Hospital
Osaka, Japan
Kindai University Hospital
Osaka, Japan
Tokyo Women's Medical University Hospital
Tokyo, Japan
National Center of Neurology and Psychiatry
Tokyo, Japan
Hospital Kuala Lumpur
Kuala Lumpur, FED. Territory of Kuala Lumpur, Malaysia
NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS
Katowice, Poland
M.A. - LEK A. M. Maciejowscy SC. Centrum Terapii SM
Katowice, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie; Klinika Neurologii
Lublin, Poland
Uniwersyteckie Centrum Kliniczne WUM, Centralny Szpital Kliniczny; Klinika Neurologii
Warsaw, Poland
Instytut Psychiatrii i Neurologii
Warsaw, Poland
Miedzyleski Szpital Specjalistyczny w Warszawie
Warsaw, Poland
San Juan MS Center
Guaynabo, Puerto Rico
SC Clubul Sanatatii SRL
Campulung Muscel, Romania
Korea University Anam Hospital
Seoul, South Korea
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.